Longeveron LLC
Price & Volume
Stats
See more52W Range | $0.47-$1.80 |
Market Cap | $25.7M |
Shares Short | 2M |
Financials
See moreRevenue (12 Mos) | $1.2M |
Revenue Growth (YoY) | 4.5% |
Gross Profit (12 Mos) | $792,000 |
Diluted EPS | -$1.16 |
News
See moreYahoo Finance • 16 days ago
Longeveron anticipates August 2026 ELPIS II readout while shifting to an asset-light partnering model
Yahoo Finance • 21 days ago
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Yahoo Finance • last month
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
Yahoo Finance • 2 months ago
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
About
CFO | Ms. Lisa A. Locklear M.B.A. |
Address | Life Science & Technology Park, Miami, FL, United States, 33136 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 38 |